Education
About Us
Working with TipRanks
Follow Us
Candel Therapeutics (CADL)
NASDAQ:CADL
CADL Analyst Ratings
Strong Buy
5 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
CADL Stock 12 Month Forecast
Average Price Target
$18.33
▲(188.66% Upside)
| Highest Price Target$25.00 | Average Price Target$18.33 | Lowest Price Target$7.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Canaccord Genuity
$25
Buy
293.70%
Upside
Reiterated
12/12/25
LifeSci Capital
$16
Buy
151.97%
Upside
Reiterated
12/08/25
Candel Therapeutics' Promising CAN-2409 Program Drives Buy Rating Amid Positive Phase 3 Results and Expert EndorsementsLast week, Candel (Nasdaq: CADL) hosted a to review their pipeline programs and provide a corporate update. Candel’s lead program, called CAN-2409, is a locally-administered, replicaon- defecv e adenovirus that delivers the herpes simplex virus thymidine kinase (HSV-tk) gene to paen ts’ tumors.
H.C. Wainwright
$23
Buy
262.20%
Upside
Reiterated
12/08/25
Citi
$24
Buy
277.95%
Upside
Reiterated
12/07/25
Bank of America Securities
$7
Hold
10.24%
Upside
Reiterated
12/05/25
Candel Therapeutics: Promising Developments Amidst Regulatory and Market ChallengesWe do think there are treatment benefits with CAN-2409 (and potentially with CAN- 3110 though data is early) based on data seen to date. We think increasingly important heading into later-stage trials/approval will be regulatory path and physician sentiment for uptake (with planned activities of engagement with KOLs, advocacy, and coverage/access). The recent debt deal with Trinity Capital should help keep CAN-2409 in NSCLC in Candel’s hands though we expect additional financing may be needed in the next few years. We maintain our Neutral rating and $7 PO.
Stephens
$15
Buy
136.22%
Upside
Initiated
10/28/25
Freedom Capital Markets
$13
Buy
104.72%
Upside
Initiated
07/14/25
Brookline Capital Markets
$25
Buy
293.70%
Upside
Initiated
07/09/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Canaccord Genuity
$25
Buy
293.70%
Upside
Reiterated
12/12/25
LifeSci Capital
$16
Buy
151.97%
Upside
Reiterated
12/08/25
Candel Therapeutics' Promising CAN-2409 Program Drives Buy Rating Amid Positive Phase 3 Results and Expert EndorsementsLast week, Candel (Nasdaq: CADL) hosted a to review their pipeline programs and provide a corporate update. Candel’s lead program, called CAN-2409, is a locally-administered, replicaon- defecv e adenovirus that delivers the herpes simplex virus thymidine kinase (HSV-tk) gene to paen ts’ tumors.
H.C. Wainwright
$23
Buy
262.20%
Upside
Reiterated
12/08/25
Citi
$24
Buy
277.95%
Upside
Reiterated
12/07/25
Bank of America Securities
$7
Hold
10.24%
Upside
Reiterated
12/05/25
Candel Therapeutics: Promising Developments Amidst Regulatory and Market ChallengesWe do think there are treatment benefits with CAN-2409 (and potentially with CAN- 3110 though data is early) based on data seen to date. We think increasingly important heading into later-stage trials/approval will be regulatory path and physician sentiment for uptake (with planned activities of engagement with KOLs, advocacy, and coverage/access). The recent debt deal with Trinity Capital should help keep CAN-2409 in NSCLC in Candel’s hands though we expect additional financing may be needed in the next few years. We maintain our Neutral rating and $7 PO.
Stephens
$15
Buy
136.22%
Upside
Initiated
10/28/25
Freedom Capital Markets
$13
Buy
104.72%
Upside
Initiated
07/14/25
Brookline Capital Markets
$25
Buy
293.70%
Upside
Initiated
07/09/25
Best Analysts Covering Candel Therapeutics
1 Month
xxx
Success Rate
4/6 ratings generated profit
Average Return
+6.72%
reiterated a xxx
rating 8 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +6.72% per trade.
3 Months
xxx
Success Rate
5/6 ratings generated profit
Average Return
+5.30%
reiterated a xxx
rating 8 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 83.33% of your transactions generating a profit, with an average return of +5.30% per trade.
1 Year
Success Rate
5/6 ratings generated profit
Average Return
+10.82%
reiterated a buy rating 8 days ago
Copying Andres Y. Maldonado's trades and holding each position for 1 Year would result in 83.33% of your transactions generating a profit, with an average return of +10.82% per trade.
2 Years
xxx
Success Rate
5/6 ratings generated profit
Average Return
+10.82%
reiterated a xxx
rating 8 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 83.33% of your transactions generating a profit, with an average return of +10.82% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
CADL Analyst Recommendation Trends
Rating
Aug 25
Sep 25
Oct 25
Nov 25
Dec 25
Strong Buy
10
8
10
12
12
Buy
0
0
0
0
0
Hold
0
1
2
3
3
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
10
9
12
15
15
Each month's total comprises the sum of three months' worth of ratings.
CADL Financial Forecast
CADL Stock Forecast FAQ
What is CADL’s average 12-month price target, according to analysts?
Based on analyst ratings, Candel Therapeutics’s 12-month average price target is 18.33.
What is CADL’s upside potential, based on the analysts’ average price target?
Candel Therapeutics has 188.66% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is CADL a Buy, Sell or Hold?
Candel Therapeutics has a consensus rating of Strong Buy which is based on 5 buy ratings, 1 hold ratings and 0 sell ratings.
What is Candel Therapeutics’s price target?
The average price target for Candel Therapeutics is 18.33. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $25.00 ,the lowest forecast is $7.00. The average price target represents 188.66% Increase from the current price of $6.35.
The highest analyst price target is $25.00 ,the lowest forecast is $7.00. The average price target represents 188.66% Increase from the current price of $6.35.
What do analysts say about Candel Therapeutics?
Candel Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.
How can I buy shares of CADL?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.